Windtree Therapeutics Receives Nasdaq Delisting Determination
Reading Time: < 1 minute
Windtree Therapeutics, Inc. announced today that it received a formal delisting determination from The Nasdaq Stock Market LLC.
The decision, notified to the Company on August 19, 2025, is a result of Windtree’s non-compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share.
As detailed in the Form 8-K filed with the U.S. Securities and Exchange Commission, Nasdaq will suspend trading of the Company’s common stock effective at the opening of business on August 21, 2025. CEO Jed Latkin formally disclosed the notification in the filing.
The company’s shares have traded below the $1 threshold since May and have experienced a significant decline in value throughout the year.
Follow and like us on
